Best Doctors for Chemotherapy in Delhi NCR, India

Dr. Ranjan is a Senior Consultant in Medical Oncology at BLK-Max Super Speciality Hospital in New Delhi, bringing over 45 years of clinical excellence to cancer care. With a distinguished academic background including MBBS, MD in Psychiatry and Paediatrics, and DNB in Medical Oncology, he has established himself as a trusted leader in comprehensive oncology treatment across multiple subspecialties. Dr. Ranjan's clinical expertise spans the full spectrum of solid tumour management, including breast cancer, head and neck cancers, gastrointestinal malignancies, lung cancer, and gynaecologic cancers. He is particularly skilled in designing and delivering multimodal treatment strategies—combining chemotherapy, immunotherapy, targeted molecular therapy, and hormonal interventions—tailored to each patient's tumour biology and individual needs. His proficiency in immune checkpoint inhibitor therapy, biomarker-driven treatment selection, and both adjuvant and neoadjuvant chemotherapy protocols reflects his commitment to contemporary, evidence-based oncology practice. Dr. Ranjan has developed a strong international patient practice, regularly treating patients from the Gulf States, Africa, and South Asia who seek advanced cancer care in India. His patient-centric philosophy emphasizes clear communication, detailed treatment planning, and compassionate management throughout the cancer journey, including palliative care options when appropriate. Patients value his balanced approach to balancing treatment efficacy with quality of life. BLK-Max Super Speciality Hospital, where Dr. Ranjan practices, is a leading tertiary cancer centre in Delhi equipped with advanced diagnostic imaging, dedicated oncology theatres, and comprehensive supportive care facilities. The hospital's multidisciplinary tumour boards, experienced nursing staff, and international patient liaison team ensure seamless care coordination for overseas patients. New Delhi's strategic location, world-class infrastructure, and cost-effective treatment make it an attractive destination for complex cancer cases requiring specialist expertise.

Dr. Ashok K. Vaid is a distinguished medical oncologist and stem cell transplant specialist with more than four decades of clinical experience. He currently serves as Chairman, Medical Oncology, Hematology and Stem Cell Transplant at the Medanta Cancer Institute, Gurgaon — one of India's largest cancer programmes. Dr. Vaid established one of the largest stem cell transplant programmes in the private sector in north India. His clinical interests centre on cancer genomics, immunotherapy guidance, precision onco-therapeutics, dendritic cell therapy, and stem cell transplantation. He has performed and supervised some of the earliest bone marrow transplants in the country, including the first 25 BMTs done at his earlier institution. He earned his Doctor of Medicine (DM) in Medical Oncology from Tamil Nadu Dr. MGR Medical University, Chennai, and has authored several peer-reviewed publications. Dr. Vaid has served as Principal Investigator for more than 50 international and national clinical studies, and is a registered postgraduate teacher with the National Board of Examinations and a panel examiner for super-specialty Medical Oncology. In recognition of his exceptional contribution to medicine, the Government of India conferred upon him the prestigious Padma Shri Award in 2009.

Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in India — milestones that placed him at the frontier of oncology practice in the country during a period when these techniques were only available in the most advanced centres globally. Dr. Raina possesses specialised expertise in treating a wide spectrum of cancers including breast cancer, lung cancer, gastrointestinal cancer, urological cancer, gynaecological cancer, lymphoma, and myeloma. His contributions extend to performing approximately 400 BMTs, significantly enhancing treatment options for various cancers in India. Before joining Fortis, Dr. Raina was part of other renowned cancer hospitals such as the All India Institute of Medical Sciences (AIIMS), where during the last decade he performed the largest number of cancer-related transplants in India. He served as a Professor and Head of Medical Oncology at AIIMS, New Delhi, where he garnered immense respect for his knowledge and leadership. Throughout his career, Dr. Raina has worked across hospitals and medical institutes both in India and abroad. During his stint at AIIMS, he was the Principal Investigator of over 50 projects where he showcased his commitment to advancing oncology through rigorous scientific inquiry. He also co-founded the INDOX network, furthering collaborative research efforts in oncology. Moreover, he has been conducting the DM course for Medical Oncology for the last 15 years and has trained more than 70 residents and DM students at AIIMS, many of whom now occupy prominent positions in the field globally. He holds more than 200 publications in national and international medical journals worldwide.

Dr. Saveena Gulati Raheja is a Senior Consultant in Medical Oncology with more than 37 years of dedicated clinical experience in comprehensive cancer care. She earned her medical qualifications from the prestigious Maulana Azad Medical College, Delhi, including her MBBS and MD, and holds specialized certifications in board-certified cancer pain management (BCCPM) and palliative care (IAPC). Her extensive background positions her as a trusted voice in oncology across India and internationally. Dr. Raheja's clinical expertise spans the full spectrum of modern cancer treatment modalities: conventional chemotherapy, targeted molecular therapies, cancer immunotherapy, and CAR-T cell therapy. She specializes in hormone-directed treatments for breast, prostate, and gynecologic malignancies, and is particularly skilled in managing treatment-related side effects through integrative approaches including acupuncture and supportive care. Her holistic philosophy combines evidence-based oncology with patient-centric supportive strategies, allowing her to address not only disease control but also quality of life during and after treatment. Dr. Raheja has built a reputation for welcoming and effectively managing international patients from the Gulf Cooperation Council nations, Africa, and South Asian regions. She is fluent in English, Hindi, and Punjabi, facilitating clear communication with patients from diverse backgrounds. Her patient-first approach and emphasis on informed decision-making make her particularly valued by overseas patients seeking comprehensive cancer management in India. Practicing at Indraprastha Apollo Hospital in New Delhi, Dr. Raheja benefits from access to state-of-the-art oncology infrastructure, advanced diagnostic imaging, and multidisciplinary tumor boards. Apollo's commitment to international patient services, combined with its NABH-accredited facilities and 24/7 critical care support, creates an ideal environment for complex cancer cases. International patients choosing Dr. Raheja's care will find seamless coordination, English-speaking nursing staff, and dedicated international patient liaison teams to arrange consultations, treatment planning, and post-operative follow-up. Her pioneering work in establishing palliative care units underscores her commitment to dignified, compassionate cancer care—a philosophy especially valued by patients and families navigating advanced disease from abroad.

Dr. Anil Dhar is the Clinical Director and Head of Medical Oncology at Marengo Asia Hospitals in Gurugram, bringing over 35 years of distinguished experience in managing solid tumors and malignancies. A post-doctoral fellow from the prestigious Tata Memorial Hospital in Mumbai, Dr. Dhar trained under some of India's leading oncologists and has spent his career advancing cancer care through evidence-based treatment strategies and compassionate patient management. Dr. Dhar specializes in chemotherapy for solid tumors, adjuvant and neoadjuvant regimens, targeted therapy, immunotherapy for advanced cancers, and hormone therapy for breast cancer. His clinical practice is informed by biomarker-based precision medicine, allowing him to tailor treatment to each patient's unique tumor profile. Throughout his career, he has treated over 35,000 patients and is recognized for his expertise in pediatric oncology and palliative care, ensuring comprehensive support across all stages of disease. He has mentored hundreds of medical and DNB oncology residents, shaping the next generation of cancer specialists across AFMC Pune, MUHS, Delhi University, and DNB programs nationally. Dr. Dhar has extensive experience welcoming international patients from the Gulf region, Africa, and beyond. He is fluent in English and Hindi, and his team at Marengo Asia Hospitals is experienced in coordinating care, visa assistance, and family counseling for overseas patients. His holistic approach extends beyond chemotherapy to include preventive oncology, cancer awareness education, long-term survivorship planning, and family support—ensuring patients receive coordinated, compassionate care throughout their cancer journey. Marengo Asia Hospitals in Gurugram is a accredited multispecialty facility well-equipped for complex oncology cases, with dedicated chemotherapy infusion centers, advanced diagnostic imaging, and dedicated international patient services. The hospital's location near Delhi and robust infrastructure make it an ideal destination for international patients seeking quality cancer care in India. Dr. Dhar's combination of military medical service experience, academic credentials, and patient-centered philosophy makes him a trusted choice for families seeking expert oncology care abroad.

Dr. Harsh Dua is a Senior Consultant Medical Oncologist at Indraprastha Apollo Hospital in New Delhi, bringing over 35 years of dedicated clinical experience in comprehensive cancer care. Holding qualifications in MBBS and MD, he has established himself as a trusted oncology specialist delivering evidence-based treatment and compassionate patient management across a broad spectrum of malignancies. Dr. Dua's clinical expertise spans the full range of modern oncology practice, including chemotherapy administration, cancer immunotherapy, targeted molecular therapies, hormone therapy for breast and prostate cancers, CAR-T cell therapy, and advanced radiation techniques including brachytherapy and stereotactic body radiation therapy. His patient-centric approach ensures that each treatment plan is individually tailored to the patient's clinical profile, disease stage, and personal circumstances. Throughout his career, he has maintained a focus on staying current with the latest advances in oncology, enabling him to offer cutting-edge therapeutic options alongside conventional care. Dr. Dua regularly treats patients from across India, the Gulf region, and international destinations seeking specialized cancer treatment in Delhi. He is fluent in English and Hindi, facilitating clear communication with diverse patient populations. His commitment to patient education empowers individuals and families to understand their diagnoses and participate actively in treatment decisions, fostering a collaborative relationship built on trust and transparency. Indraprastha Apollo Hospital, where Dr. Dua practices, is a leading multi-specialty tertiary care centre equipped with state-of-the-art oncology facilities, including dedicated chemotherapy units, advanced radiation therapy suites, and comprehensive supportive care services. The hospital's robust infrastructure, coupled with Dr. Dua's extensive experience, makes it an ideal destination for international patients seeking world-standard cancer care in India. For those considering treatment abroad, Gaf Healthcare facilitates seamless coordination of consultations, medical records transfer, and treatment logistics.

Dr. Jyoti Wadhwa is one of India's most accomplished medical oncologists and precision oncology specialists, bringing over 32 years of dedicated clinical experience in comprehensive, evidence-based cancer care. A Fellow of the Royal College of Physicians (FRCP), Edinburgh, and graduate of AIIMS with a DM in Medical Oncology, she stands among the country's foremost cancer specialists. Her advanced international training at Imperial College London has further strengthened her expertise in cutting-edge oncological practice. As Principal Lead – Medical Oncology & Precision Oncology at Apollo Athenaa Women's Cancer Centre in Defence Colony, South Delhi, Dr. Wadhwa delivers a sophisticated, science-driven approach to cancer treatment. She specializes in medical oncology, precision oncology, and the full spectrum of women's cancers—breast, ovarian, cervical, and endometrial cancer. Her clinical arsenal includes chemotherapy, cancer immunotherapy, targeted therapy, antibody-drug conjugates, hormone therapy, and CAR-T cell therapy. She is a passionate advocate of molecular profiling, genetic testing, biomarker analysis, and liquid biopsies, tailoring every treatment plan to the individual tumor biology and patient circumstances. Dr. Wadhwa has built a robust international patient practice, welcoming patients from the Gulf Cooperation Council (GCC), North Africa, and across South Asia seeking world-class cancer care. Her warm, empathetic communication style—fluent in both English and Hindi—puts patients and families at ease during what can be a daunting journey. She is recognized not only as a clinician but also as an oncology educator and author of two highly regarded medical books, having delivered over 400 scientific lectures at national and international conferences. Apollo Athenaa Women's Cancer Centre is a dedicated tertiary cancer facility embedded within the Apollo Hospitals network, known for its state-of-the-art diagnostic imaging, molecular pathology laboratories, multidisciplinary tumor boards, and patient-centered supportive care. The centre's commitment to precision medicine, combined with Apollo's international patient infrastructure, makes it an ideal destination for international patients seeking personalized oncology care. International patients benefit from streamlined visa support, translation services, and coordinated follow-up care. Whether you are seeking a second opinion, initial diagnosis and staging, or complex multimodal treatment, Dr. Wadhwa and Apollo Athenaa provide the clinical excellence and compassionate support that international patients expect. With Gaf Healthcare's coordination, your entire care journey—from virtual consultation through in-person treatment and remote follow-up—is seamlessly managed.

Dr. R Ranga Rao is Chairman of Medical Oncology at Paras Hospitals in Gurugram, bringing over 32 years of specialised experience in the diagnosis and treatment of solid tumours. A highly qualified medical oncologist, Dr. Rao holds an MBBS from Jawaharlal Nehru Medical College, MD from the Armed Forces Medical College Pune, and a postgraduate diploma in Medical Oncology from the Cancer Institute, Adyar—one of Asia's leading cancer centres. His impressive academic pedigree and clinical journey reflect a deep commitment to advancing oncological care. Dr. Rao's clinical practice encompasses a comprehensive range of therapeutic approaches, including chemotherapy for solid tumours, targeted molecular therapy, biomarker-guided treatment selection, hormone therapy for breast cancer, and increasingly, immunotherapy using immune checkpoint inhibitors. His multidisciplinary approach integrates adjuvant, neoadjuvant, and palliative chemotherapy protocols tailored to each patient's cancer stage and individual circumstances. He has trained extensively at world-renowned centres including MD Anderson Cancer Centre in Houston, Dana Farber Cancer Institute in Boston, and the Royal Marsden Hospital in London—knowledge he continuously applies in clinical practice. The hospital attracts a significant international patient population, with patients travelling from the Gulf Cooperation Council countries, East Africa, and South Asia seeking Dr. Rao's expertise. His experience managing patients across diverse geographic and cultural backgrounds has honed his ability to communicate complex treatment plans clearly and ensure patient confidence in their care. Dr. Rao remains actively engaged with international medical communities as a member of ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology), and ISMPO (Indian Society of Medical & Paediatric Oncology). Paras Hospitals in Gurugram is recognised for its advanced oncology infrastructure, comprehensive cancer centre facilities, and commitment to multidisciplinary care. The hospital provides seamless support for international patients, including dedicated international patient services, translation assistance, and coordinated follow-up care. International patients value the combination of affordable, high-quality cancer treatment delivered by experienced specialists in a modern hospital setting. The city of Gurugram offers good connectivity via Delhi's international airport, a well-established network of hotels and recovery centres, and increasing recognition as a medical tourism hub for cancer care in India.

Dr. Satya Pal Kataria is Vice-Chairman of Medical Oncology at Medanta - The Medicity in Gurugram, bringing over 28 years of distinguished clinical experience in cancer care. A graduate of JIPMER, Pondicherry (MBBS and MD in General Medicine) and AIIMS, New Delhi (DM in Medical Oncology), he has honed his expertise through decades of dedicated practice at premier Indian institutions. His career trajectory reflects an exceptional commitment to oncological excellence, including a prolonged tenure at VMMC – Safdarjung Hospital, New Delhi, where he rose to head the Department of Medical Oncology. Dr. Kataria specializes in comprehensive cancer management across multiple modalities. His clinical focus encompasses adjuvant and neoadjuvant chemotherapy, advanced immunotherapy including immune checkpoint inhibitor therapy, molecular targeted therapy, and hormone-based treatments for breast and prostate cancers. He is particularly skilled in biomarker-guided therapeutic selection, allowing him to tailor treatment plans to each patient's individual tumour biology. His expertise extends to palliative chemotherapy, ensuring compassionate care for patients with advanced disease. Over three decades, he has managed thousands of cancer patients with a reputation for rigorous clinical judgment and outcome-oriented practice. Dr. Kataria welcomes international patients from across the Gulf region, Africa, and South Asia, and has considerable experience managing complex oncology cases in a multicultural setting. He is fluent in English and Hindi, facilitating clear communication with diverse patient populations. Medanta's international patient services team assists with documentation review, pre-treatment planning, and remote consultations via video, making access seamless for those traveling from abroad. Medanta - The Medicity stands as one of India's leading tertiary care institutions, recognised for its world-class oncology infrastructure. The hospital boasts state-of-the-art chemotherapy suites, advanced diagnostic imaging (PET-CT, MRI), molecular pathology laboratories for biomarker testing, and dedicated inpatient oncology wards with 24/7 critical care support. Located in Gurugram's healthcare corridor, Medanta combines academic rigour with patient-centric care, making it a preferred destination for international cancer patients seeking evidence-based, personalised treatment. International patients choosing Dr. Kataria benefit from his decades of clinical leadership, access to cutting-edge cancer therapeutics, and Medanta's comprehensive support infrastructure. His 32+ publications in reputed Indian and international journals reflect his ongoing commitment to advancing medical oncology through research and scholarly contribution. Whether seeking a second opinion, initial diagnosis, or complex treatment planning, patients receive care grounded in the latest oncological evidence and delivered with the institutional rigour of a premier Indian medical centre.

Dr. Nitin Sood is Vice Chairman of the Hematology department at Medanta — The Medicity in Gurgaon, one of India's leading tertiary-care institutions. With over 28 years of clinical experience, he is a highly trained hematologist and medical oncologist holding advanced qualifications including FRCPath, MRCPath, and MRCP (UK). His credentials reflect a rigorous educational pathway: MBBS from Mysore University (1998), MD in General Medicine and DNB in Internal Medicine from Delhi University (both 2002), and specialized training in clinical hematology through a CCT qualification completed in the United Kingdom. Dr. Sood's clinical expertise spans the full spectrum of hematologic malignancies and benign blood disorders. He has extensive experience managing acute and chronic leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes. He is particularly skilled in bone marrow and stem cell transplantation, including haploidentical transplant approaches, as well as the management of bleeding and clotting disorders, hemophilia, sickle cell disease, thalassemias, and aplastic anemia. His practice reflects both diagnostic acumen and therapeutic sophistication, supported by high patient volumes and contemporary clinical protocols. Dr. Sood regularly treats patients from across the Gulf region, Africa, and the broader international community who seek specialized hematology and oncology care. His fluency in English and Hindi, combined with Medanta's robust international patient services, ensures seamless communication and coordinated care for overseas patients. He understands the complexities of traveling for treatment and tailors clinical schedules and follow-up arrangements accordingly. Medanta — The Medicity is accredited by NABH and JCI, with state-of-the-art hematology laboratories, dedicated stem cell transplant units, and on-site oncology services. The hospital's location in Gurgaon provides excellent connectivity via Delhi, and the institution maintains dedicated international patient coordinators who assist with visa facilitation, accommodation, and treatment logistics. For international patients seeking expert hematology and oncology care in India, Dr. Sood's profile at Medanta represents a compelling combination of clinical depth, institutional infrastructure, and patient-centered support.

Dr. Hari Goyal is Chief of Medical Oncology at Artemis Hospital in Gurgaon, bringing over 27 years of specialized experience in comprehensive cancer care. He holds an MBBS, MD in Internal Medicine, and a DM in Medical Oncology from the All India Institute of Medical Sciences (AIIMS), New Delhi—one of India's premier medical institutions. His training also includes foundational work at the Tata Memorial Hospital in Mumbai, a leading cancer research and treatment centre, which shaped his approach to evidence-based oncology. Dr. Goyal's clinical expertise encompasses targeted therapy for solid tumours, cancer immunotherapy, advanced chemotherapy protocols, and specialized hormone therapies for breast, gynaecological, and prostate cancers. He has developed considerable depth in managing metastatic and Stage 4 cancers, including those with spread to vital organs such as the lungs and brain. Beyond clinical practice, he has been actively involved in clinical research and drug development, contributing to innovations that mitigate chemotherapy-related side effects—work with global relevance. His approach to personalised oncology has consistently improved survival outcomes and quality of life for patients with advanced disease. Dr. Goyal has earned recognition for treating patients from over 29 countries, making him a sought-after oncologist for complex international cases. He regularly manages patients from the Gulf region, Africa, and South Asia, and brings a culturally sensitive, patient-centred approach to their care. His fluency in English and Hindi facilitates clear communication with diverse patient populations. The international patient community values his meticulous case review, transparent treatment planning, and commitment to outcome-focused care. Artemis Hospital, his current base in Gurgaon, is a modern, well-equipped tertiary centre with advanced diagnostic and therapeutic facilities. The hospital's oncology unit benefits from Dr. Goyal's leadership and maintains high standards for inpatient care, outpatient consultation, and palliative support. Gurgaon's connectivity to Delhi airport and its proximity to North India's business hubs make it convenient for international patients seeking second opinions or active treatment. Dr. Goyal's ICH-GCP certification underscores his commitment to research ethics and clinical trial excellence, assuring international patients of globally aligned standards of care. International patients choosing Dr. Goyal can expect evidence-based treatment recommendations, transparent communication about prognosis and options, and continuity of care coordinated through Gaf Healthcare's support network. His role as Chief allows him to influence departmental protocols and ensure that international standards of oncology practice are maintained.

Dr. P.K. Das is a Senior Consultant in Medical Oncology and Hemato-Oncology at Indraprastha Apollo Hospital in New Delhi, with over 25 years of clinical experience dedicated to comprehensive cancer care. He holds an MBBS degree, MD in Internal Medicine, and a prestigious DM in Medical Oncology from AIIMS, one of India's premier medical institutions. His career has been marked by a commitment to evidence-based oncology and patient-centered treatment planning. Dr. Das has successfully completed more than 100,000 chemotherapy procedures throughout his career, demonstrating exceptional clinical depth and technical mastery. His expertise spans the full spectrum of modern cancer treatment: chemotherapy for solid tumors (both adjuvant and neoadjuvant), immune checkpoint inhibitor therapy, molecular targeted therapy based on biomarkers, hormone therapy for breast and gynecologic malignancies, and palliative care. He is known for tailoring individualized treatment protocols that address not only the physical aspects of cancer but also the mental and emotional well-being of his patients. Dr. Das regularly treats international patients from the Gulf region, East Africa, and the Indian subcontinent who seek his expertise. His fluency in English and Hindi, combined with his international medical network, makes him accessible to international medical tourists. Indraprastha Apollo Hospital provides dedicated international patient services, ensuring seamless coordination for overseas patients throughout their treatment journey. Indraprastha Apollo Hospital is a JCI-accredited tertiary care center renowned for oncology excellence, equipped with advanced diagnostic imaging, modern chemotherapy units, and comprehensive supportive care facilities. The hospital's international patient department and multilingual staff create a welcoming environment for medical tourists. Dr. Das serves as Academic Coordinator at the hospital, reflecting his role in advancing cancer care standards and training the next generation of oncologists. Dr. Das holds prestigious professional memberships including the Indian Society of Medical Oncology (ISMPO), Life Membership in the European Society of Medical Oncology (ESMO), and membership in the American Society of Clinical Oncology (ASCO). He is also an expert member of the Drug Controller General of India's committee and the Expert Advisory Committee on Oncology under the Ministry of Health and Family Welfare, Government of India. For international patients seeking world-class oncology care in India, Dr. Das represents a trusted option combining decades of experience with institutional excellence.

Dr. Dharma Choudhary is Chairman of Haemato-Oncology and Bone Marrow Transplant at BLK-Max Super Speciality Hospital in New Delhi, bringing over 23 years of clinical expertise in blood disorders and transplant medicine. He holds a DM in Clinical Haematology from AIIMS New Delhi and is a life member of the Indian Society of Haematology & Transfusion Medicine, as well as a member of the American Society of Blood and Marrow Transplant. His academic foundation spans fellowships at leading centres including Christian Medical College Vellore, Sanjay Gandhi Post Graduate Institute Lucknow, and the BC Cancer Agency in Vancouver, establishing him as a globally trained specialist. Dr. Choudhary has performed over 2,000 bone marrow transplants, making him one of India's most accomplished transplant surgeons. His clinical repertoire encompasses allogeneic, autologous, and haploidentical transplants, alongside matched sibling donor transplantation. He treats acute leukaemias, myelodysplastic syndromes, bone marrow failure syndromes, and solid tumour chemotherapy with equal proficiency. His systematic approach to patient evaluation and post-transplant care has built a reputation for achieving strong clinical outcomes in complex haematological malignancies. International patients from the Gulf states, Africa, and South Asia regularly travel to New Delhi for Dr. Choudhary's consultation and transplant programmes. He manages the full treatment journey—from initial diagnosis and donor evaluation through long-term follow-up—and works closely with Gaf Healthcare to streamline referrals, arrange local accommodation, and provide interpreter support for non-Hindi-speaking patients. His compassionate communication style and willingness to discuss alternative treatment options make him a trusted advisor for families facing challenging blood disorders. BLK-Max Super Speciality Hospital is one of India's premier multi-specialty centres with NABH accreditation, dedicated bone marrow transplant ICU facilities, and a robust international patient services desk. The hospital's proximity to Delhi's international airport and its established infrastructure for managing complex transplant cases make it a natural hub for medical tourism in haemato-oncology. Dr. Choudhary's leadership position ensures that international patients receive coordinated care with access to allied specialists, diagnostic imaging, and transfusion medicine under one roof, reducing logistical fragmentation and improving treatment continuity.

Dr. Ankit Jain is a Senior Consultant in Medical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of distinguished clinical experience in cancer care. He holds an MBBS from Maulana Azad Medical College Delhi, MRCP qualifications in Medicine and Oncology from London, and an MSc in Oncology from Birmingham, United Kingdom. His training across prestigious UK and Indian institutions has shaped a career devoted to evidence-based, internationally-standard oncological practice. Dr. Jain specializes in comprehensive cancer management spanning chemotherapy, cancer immunotherapy, targeted therapy, and hormonal treatments across multiple cancer types. His clinical expertise covers bowel cancer, lung cancer, breast cancer with hormone therapy, kidney cancer, pancreatic cancer, and gynaecologic malignancies. He is skilled in CAR-T cell therapy, radiation therapy coordination, and personalized treatment planning. His practice is underpinned by continuous engagement with the latest oncological advances and a commitment to multidisciplinary care protocols. International patients form a meaningful part of Dr. Jain's patient base, particularly from the Gulf region, Africa, and South Asian countries. He communicates fluently in English, Hindi, and Punjabi, ensuring that patients from diverse backgrounds feel supported and informed throughout their treatment journey. His approachable clinical demeanour combined with his depth of knowledge makes him a trusted choice for patients seeking second opinions and comprehensive cancer care plans. Indraprastha Apollo Hospital in New Delhi is one of India's leading tertiary cancer centres, equipped with advanced imaging, robotic-assisted surgical suites, and dedicated oncology wings. The hospital maintains NABH and JCI accreditation, international patient support services, and robust follow-up protocols. Dr. Jain's affiliation with Apollo Athena Women's Cancer Centre further underscores his commitment to specialized oncological care. Dr. Jain is an active member of the American Society of Clinical Oncologist, European Society of Medical Oncologist, and the British Medical Association, maintaining alignment with global best practices. International patients choosing to work with him benefit from a clinician trained in both NHS and Indian healthcare systems, ensuring world-class standards and culturally sensitive care.

Dr. Chandragouda Dodagoudar is a Senior Director and Unit Head of Medical Oncology at BLK-Max Super Speciality Hospital in New Delhi, bringing over 22 years of clinical expertise in comprehensive cancer care. His credentials include MBBS, MD in Medicine, DNB in Medical Oncology, and ECMO qualification from Europe, positioning him as a deeply trained specialist in systemic cancer treatment. Dr. Dodagoudar has developed particular depth across a wide spectrum of oncological conditions—including head and neck cancer, breast cancer, lung cancer, thoracic cancer, thyroid cancer, gastrointestinal malignancies, gynaecologic cancers, urological cancers, sarcomas, bone cancers, and lymphomas. He is especially skilled in adjuvant and neoadjuvant chemotherapy, palliative chemotherapy, immunotherapy with immune checkpoint inhibitors, hormone therapy for breast and gynaecologic cancers, and molecular targeted therapy guided by biomarker analysis. His evidence-based approach combines cutting-edge systemic therapies with individualised treatment planning. International patients from the Gulf countries, Africa, and across South Asia regularly seek his care, drawn by his patient-centric philosophy and transparent communication. He works closely with Gaf Healthcare to facilitate seamless consultations via video conferencing, document review, and coordinated care pathways for medical tourists. His fluency in English and Hindi helps him connect with diverse patient populations and explain complex treatment options clearly. BLK-Max Super Speciality Hospital, where Dr. Dodagoudar leads the oncology unit, is one of India's premier multi-specialty centres with NABH accreditation, advanced diagnostic imaging, dedicated chemotherapy infusion centres, and robust supportive care infrastructure. The hospital has established international patient services, airport liaison, accommodation coordination, and experienced nursing staff trained in international protocols. For international patients, this combination of Dr. Dodagoudar's expertise and BLK-Max's infrastructure ensures comprehensive, safe, and cost-effective cancer treatment in a world-class setting. Patients from overseas benefit from competitive treatment costs, direct access to a senior oncologist, and the ability to continue follow-up care through telemedicine with Gaf Healthcare support.

Dr. Jyoti Anand is an Additional Director of Medical Oncology at Fortis Hospital, Noida, with over 22 years of clinical experience in the diagnosis and comprehensive treatment of solid tumors and hematological malignancies. She holds postgraduate qualifications including DNB in Internal Medicine and DNB in Medical Oncology, establishing a strong foundation in evidence-based oncological practice. Her academic credentials and professional memberships with the Association of Physicians of India (API), European Society of Medical Oncology (ESMO), and Indian Medical Association (IMA) reflect her commitment to advancing cancer care through international best practices. Dr. Anand specializes in the full spectrum of chemotherapy treatments, including adjuvant, neoadjuvant, and palliative regimens tailored to individual patient pathology and performance status. She has extensive experience administering modern immunotherapies and immune checkpoint inhibitor therapies for advanced-stage cancers, bringing precision-medicine approaches to patient management. Her clinical work encompasses solid tumors across multiple organ sites, with a focus on multidisciplinary treatment planning and optimal outcomes. International patients from the Gulf region, Africa, and South Asia form a significant part of her practice. Dr. Anand is known for her compassionate, patient-centered approach and her ability to communicate complex treatment plans clearly to patients from diverse linguistic and cultural backgrounds. She takes time to address patient concerns and involves families in the decision-making process, ensuring adherence to treatment protocols and psychological well-being throughout the cancer journey. Fortis Hospital, Noida, is a JCI-accredited tertiary care center with comprehensive oncology infrastructure, including state-of-the-art chemotherapy suites, advanced imaging, and multidisciplinary tumor boards. The hospital's international patient services team facilitates seamless coordination for overseas patients, from initial consultation to post-treatment follow-up. Located in the Delhi NCR region, Fortis Noida offers excellent connectivity and is well-positioned to serve patients from across South Asia and beyond. International patients choosing Dr. Anand benefit from her deep expertise in evidence-based cancer care, her proficiency in English and Hindi, and the hospital's established protocols for international patient management. Whether undergoing initial chemotherapy or seeking a second opinion on treatment strategy, patients can expect rigorous diagnostic review, transparent discussion of options, and compassionate oversight throughout their cancer care journey.

Dr. Mohit Sharma is a Clinical Director and Head of the Department of Medical Oncology at Marengo Asia Hospitals in Faridabad, bringing over 20 years of dedicated expertise in comprehensive cancer care. He earned his MBBS and MD in Medicine from Government Medical College, Jammu, and completed specialized training in medical oncology through academic posts at VMMC & Safdarjung Hospital, New Delhi, and a postdoctoral fellowship at the renowned Tata Memorial Hospital, Mumbai. Throughout his career, Dr. Sharma has developed deep clinical competence across a wide spectrum of malignancies, including head and neck, breast, lung, gastrointestinal, genitourinary, gynecological, bone, and soft tissue cancers. He is particularly skilled in precision oncology approaches, including chemotherapy, cancer immunotherapy, targeted therapy, and emerging modalities such as CAR-T cell therapy. His experience spans hormone therapy for breast, gynecological, and prostate cancers, allowing him to tailor treatment plans to individual patient biology and disease stage. Dr. Sharma has earned a strong reputation for patient-centric care and regularly treats international patients from the Gulf region, Africa, and SAARC countries seeking specialized oncology services in India. His ability to communicate in English and Hindi facilitates seamless consultations with diverse patient populations. At Marengo Asia Hospitals, he directs a comprehensive oncology department equipped with modern diagnostic and therapeutic facilities, ensuring that both domestic and international patients receive evidence-based, multidisciplinary cancer care. Marengo Asia Hospitals is a modern, multi-specialty tertiary care center in Faridabad with advanced oncology infrastructure, dedicated ICU support, and an established international patient services team. The hospital's strategic location near Delhi makes it accessible for patients traveling from abroad. Dr. Sharma's leadership of the oncology department and his active membership in the European Society of Medical Oncology (ESMO), Indian Society of Oncology, and the Indian Cooperative Oncology Network (ICON) reflect his commitment to maintaining international standards of cancer care. For international patients considering cancer treatment in India, Dr. Sharma offers a proven combination of extensive experience, modern clinical practice, and a compassionate approach to oncology management. His track record at prestigious institutions like Tata Memorial Hospital and Fortis Healthcare demonstrates consistent excellence in delivering outcomes-focused cancer treatment.

Dr. Priya Tiwari is the Head of the Department of Medical Oncology at Artemis Hospital, Gurugram, and brings over 20 years of clinical expertise to cancer care. A distinguished graduate of the All India Institute of Medical Sciences (AIIMS), she holds an MD in Medicine and a DM in Medical Oncology, credentials that anchor her practice in rigorous evidence-based oncology. Her educational foundation at Jawaharlal Nehru Medical College, Banaras Hindu University (MBBS, 2006) reflects a career built on academic excellence—she secured the highest marks in her final exams and was recognized as the best outgoing female candidate at her institute. Dr. Tiwari's clinical depth spans a broad spectrum of malignancies, including breast cancer, gynecological cancers, gastrointestinal and hepatobiliary cancers, colorectal and lung cancers, brain tumors, and soft tissue sarcomas. She is particularly skilled in immunotherapy for solid tumors, hormonal therapy for hormone-responsive cancers, molecular targeted therapy based on biomarkers, and chemotherapy—both adjuvant and palliative. Her areas of interest also encompass cancer genetics and precision medicine, reflecting her commitment to personalized cancer treatment. She is an ESMO-certified Medical Oncologist and has pursued advanced training through preceptorships on kidney cancer in Taiwan (2015) and received travel grants to prestigious international forums including ESMO Asia in Singapore and oncology conferences in Sweden. Dr. Tiwari is highly experienced in managing international patients from across the Gulf region, Africa, and other geographies. She adopts a multidisciplinary approach to cancer management, addressing not only the disease but also the holistic concerns of her patients. Her practice reflects a deep commitment to palliative care and end-of-life support, ensuring that every patient receives compassionate, dignified treatment regardless of their cancer stage. She is fluent in English and Hindi, facilitating clear communication with patients from diverse backgrounds. Artemis Hospital, Gurugram is one of India's leading multispecialty healthcare institutions, accredited by NABH and equipped with state-of-the-art oncology facilities, advanced diagnostic imaging, and a dedicated cancer support infrastructure. The hospital's international patient services and comprehensive post-treatment follow-up protocols make it a preferred destination for cancer care. International patients can expect seamless coordination, transparent treatment planning, and access to cutting-edge therapies under Dr. Tiwari's expert oversight. For patients seeking specialized cancer treatment with a physician who balances clinical rigor with compassionate care, Dr. Tiwari's experience and hospital affiliation offer both clinical depth and logistical comfort. Her memberships in the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and the Immuno-oncology Society of India position her within the global oncology community, ensuring her patients benefit from the latest advances in cancer medicine.

Dr. Sandeep Singh Bali is an Associate Consultant in Medical Oncology at Medanta - The Medicity, Gurgaon, bringing over two decades of clinical experience to the field of cancer care. He holds an MBBS degree alongside advanced qualifications in Hospital Management and Clinical Research, which together equip him with a comprehensive understanding of both patient treatment and the research-driven principles that underpin modern oncology. This unique blend of medical expertise and healthcare management knowledge sets him apart in delivering structured, evidence-based care. Dr. Bali's clinical practice encompasses the full spectrum of medical oncology. He specializes in managing both hematologic malignancies—including leukemia and lymphoma—and solid tumors such as breast and lung cancers. His proficiency spans chemotherapy administration in adjuvant, neoadjuvant, and palliative settings, as well as emerging modalities including immunotherapy for advanced cancers, hormone therapy for breast cancer, and biomarker-driven targeted therapies for solid tumors. He is skilled in central venous access procedures, intrathecal therapy delivery, and bone marrow aspiration and biopsy—procedural competencies that enhance patient safety and treatment precision. Dr. Bali maintains a strong international patient practice and regularly treats patients from the Gulf, Africa, and the Indian subcontinent. His approach integrates supportive care and complication management, ensuring that patients undergoing intensive cancer treatment receive holistic attention. He is fluent in English and Hindi, facilitating clear communication with diverse patient populations. Medanta - The Medicity is a 1,250-bed tertiary teaching hospital in Gurgaon recognized for its advanced oncology infrastructure, including dedicated cancer centers, state-of-the-art radiotherapy units, and multidisciplinary tumor boards. The hospital's commitment to research and academic excellence, combined with its capacity to manage complex cases, makes it an ideal destination for international patients seeking comprehensive cancer care. International patients at Medanta benefit from dedicated medical tourism coordinators, visa assistance, and accommodation support. For international patients considering treatment in India, Dr. Bali's combination of clinical depth, research orientation, and management expertise—delivered within a well-resourced, accredited hospital setting—offers a compelling option for diagnosis, treatment planning, and long-term follow-up care in medical oncology.

Dr. Shefali Sardana is a Senior Consultant in Medical Oncology at Indraprastha Apollo Hospital in New Delhi with over 20 years of clinical expertise in cancer care. She holds an MBBS, MD in Medicine, and DNB in Medical Oncology, alongside recent fellowships in colorectal cancer management from Charité University Hospital in Berlin (2024) and kidney cancer treatment in Singapore (2019). Her qualifications and continuous engagement with international training programmes reflect her commitment to staying at the forefront of modern oncology. Dr. Sardana specialises in the comprehensive management of gastrointestinal, hepato-pancreato-biliary, and genitourinary cancers, with additional expertise in breast and gynaecological malignancies. She is highly skilled in delivering chemotherapy, immunotherapy, targeted therapy, hormone therapy, and CAR-T cell therapy. Throughout her career, she has administered and supervised over 40,000 cycles of systemic therapy and treated more than 15,000 cancer patients across early-stage, locally advanced, and metastatic disease settings. Her multidisciplinary approach to complex solid organ malignancies ensures individualised, evidence-based treatment plans. Dr. Sardana is an experienced clinical researcher and Principal Investigator in international oncology trials, with presentations at major global forums including ASCO-GI. She actively contributes to national cancer guidelines and medical textbooks, strengthening India's oncology knowledge base. She welcomes international patients from the Gulf region, Africa, and neighbouring countries, and is fluent in both English and Hindi, ensuring clear communication throughout the treatment journey. Her patient-centred philosophy combines advanced systemic therapy expertise with compassionate care. Indraprastha Apollo Hospital, where Dr. Sardana practises, is a world-renowned institution equipped with state-of-the-art oncology facilities, advanced diagnostic imaging, and robust supportive care services. The hospital's NABH and JCI accreditation, combined with dedicated international patient support, makes it an ideal destination for cancer care. Apollo Athenaa Women's Cancer Centre, affiliated with her practice, further specialises in breast and gynaecological malignancies. International patients choosing Dr. Sardana benefit from cutting-edge cancer treatment in a highly regulated healthcare environment, combined with the affordability and clinical depth that Indian oncology uniquely offers.

Dr. Ajay Sharma is the Senior Director and Unit Head of Medical Oncology at BLK-Max Super Speciality Hospital in New Delhi, bringing over 18 years of dedicated expertise in comprehensive cancer care. He is a Fellow of the European Society for Medical Oncology (ESMO) and holds the prestigious European Certification in Medical Oncology (ECMO) from Amsterdam, alongside his MD from Sher-i-Kashmir Institute of Medical Sciences and DNB in Medical Oncology from Rajiv Gandhi Cancer Institute. His clinical foundation is exceptionally strong, built on rigorous training and progressive leadership roles across India's premier oncology centres. Dr. Sharma's clinical practice spans the full spectrum of solid tumour management, with particular mastery in breast cancer, head and neck cancers, and advanced malignancies. He specialises in multimodal treatment strategies including adjuvant and neoadjuvant chemotherapy, immunotherapy for advanced cancers, immune checkpoint inhibitor therapy, and precision molecular-targeted therapies guided by biomarker analysis. His evidence-based approach to hormone therapy in breast cancer and targeted treatment of solid tumours has made him a trusted clinician within India's oncology community. As Unit Head at BLK-Max, he oversees comprehensive cancer programmes and leads multidisciplinary teams to manage complex cases. Dr. Sharma regularly treats international patients from the Gulf region, East Africa, and Central Asian countries who seek his expertise for second opinions and definitive cancer treatment. His fluency in English and Hindi, combined with his international training credentials and membership in both ASCO (American Society of Clinical Oncology) and ESMO, ensures seamless communication and globally-aligned care standards. He understands the unique needs of patients travelling for treatment, from initial consultation through follow-up management. BLK-Max Super Speciality Hospital, where Dr. Sharma practises, is one of New Delhi's most advanced oncology destinations, equipped with state-of-the-art chemotherapy suites, molecular diagnostics laboratories, and dedicated palliative care units. The hospital maintains NABH accreditation and offers robust international patient support, including visa assistance and accommodation coordination. For patients seeking medical oncology care in India, Dr. Sharma's combination of international certification, institutional leadership, and proven outcomes makes BLK-Max an excellent choice for comprehensive, evidence-based cancer treatment tailored to each patient's unique tumour biology and clinical stage.

Dr. Ankur Bahl is the Principal Director of Medical Oncology at Fortis Memorial Research Institute in Gurugram, bringing over 17 years of specialised clinical experience in cancer treatment. A graduate of Maulana Azad Medical College, Delhi, where he completed both his MBBS and MD in Medicine, Dr. Bahl furthered his expertise by obtaining his DM in Medical Oncology from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi. He has also completed a specialized course on Adverse Drug Reactions, Drug Interactions, and Pharmacovigilance at the University of Oxford, UK, strengthening his evidence-based approach to cancer care. Dr. Bahl's clinical depth encompasses the full spectrum of medical oncology, including chemotherapy for solid tumours, neoadjuvant and adjuvant chemotherapy protocols, immunotherapy using immune checkpoint inhibitors, targeted molecular therapies, and hormonal treatment for breast cancer. He is recognised as the lead author of the largest real-world Indian dataset on targeted therapy with Cetuximab in head and neck cancer, acute myeloid leukaemia treatment, and Human Papillomavirus epidemiology in the Indian population—publications that have shaped understanding of cancer patterns and treatment efficacy in the region. His commitment to evidence-based oncology is evident through his active participation in tumour boards, master classes, and workshops across India and internationally. Dr. Bahl treats a substantial international patient cohort, welcoming patients from the Gulf Cooperation Council states, African nations, and South Asian countries seeking advanced oncological care. His fluency in English and Hindi enables seamless communication with diverse patient backgrounds. He provides comprehensive supportive and palliative care alongside curative treatments, ensuring patients receive holistic management throughout their cancer journey. Fortis Memorial Research Institute, where Dr. Bahl practises, is a leading tertiary-care cancer centre in Gurugram with state-of-the-art infrastructure, dedicated oncology wards, advanced diagnostic and treatment facilities, and a strong international patient support team. The hospital maintains accreditation standards and offers integrated care with specialist nurses, nutritionists, and counsellors. International patients benefit from streamlined admission processes, translation services, and coordination of follow-up care. Dr. Bahl's position as Principal Director ensures that patients receive leadership-level oversight of their treatment strategy, with access to the latest clinical protocols and innovations in cancer therapy.

Dr. Rajat Bajaj is the Director and Unit Head of Medical Oncology at Fortis Hospital in Delhi NCR, bringing over 17 years of distinguished clinical experience in cancer care. He holds an MBBS, MD in Medicine, DNB in Medical Oncology, and credentials from the Royal College of Physicians, establishing a strong foundation in both general medicine and specialized oncology. Dr. Bajaj has earned recognition for his expertise in cutting-edge cancer treatment modalities, particularly immunotherapy and targeted molecular therapies. He administers over 700 immunotherapies annually and brings deep clinical knowledge across immune checkpoint inhibitor therapy, solid tumor chemotherapy, hormone therapy for breast cancer, and biomarker-driven treatment strategies. His comprehensive approach integrates both conventional and advanced targeted therapies, and he has served as national-level faculty for Medicine for 8 years, contributing to medical education and practice standards across India. International patients from the Gulf region, Africa, and South Asia seek his consultation for personalized cancer treatment planning. Dr. Bajaj's patient-centered approach ensures that each individual receives a tailored treatment protocol based on their specific tumor characteristics and overall health status. He is experienced in managing complex cases and has built a reputation for transparent communication and compassionate care. Fortis Hospital in Delhi NCR is a leading multispecialty institution equipped with state-of-the-art oncology facilities, advanced diagnostic imaging, and dedicated cancer care units. The hospital maintains NABH accreditation and provides comprehensive support for international patients, including multilingual staff and coordinated travel and accommodation assistance. For patients traveling from abroad, Fortis offers seamless integration with Gaf Healthcare's support services, ensuring a smooth experience from initial consultation through follow-up care.

Dr. Devender Sharma is an Associate Consultant in Medical Oncology at Medanta — The Medicity, Gurugram, with over 16 years of dedicated clinical experience. He holds an MD in Internal Medicine, a Fellowship in Pain and Palliative Care, and a Certificate in Clinical Research, positioning him as a well-rounded oncologist equipped to manage complex cancer patients with both curative and compassionate intent. Dr. Sharma's clinical expertise spans the full spectrum of malignant disease management. He specializes in solid tumor chemotherapy, including breast cancer, gastrointestinal cancers, colorectal cancer, and lung cancer. His treatment armamentarium includes adjuvant and neoadjuvant chemotherapy, hormone therapy, targeted molecular therapy, and immunotherapy for advanced cancers. This breadth of knowledge, combined with evidence-based practice, allows him to design individualized treatment protocols tailored to each patient's tumor biology and clinical stage. International patients from the Gulf region, Africa, and South Asia benefit from Dr. Sharma's experience managing diverse cancer populations and his fluency in English alongside Hindi. He is equally proficient in palliative care and pain management, ensuring holistic support throughout the patient journey. His scholarly contributions—including numerous publications and book chapters in oncology—reflect his commitment to advancing cancer care knowledge. Medanta — The Medicity is one of India's most prestigious multispecialty hospitals, located in Gurugram's central business district. The facility offers world-class oncology infrastructure, advanced diagnostic imaging, chemotherapy suites with modern supportive care, and seamless coordination for international patients. The hospital's proximity to Delhi's international airport and its established medical tourism framework make it an ideal destination for patients seeking expert cancer treatment abroad.

Dr. Vishnu Hari is an Associate Director and Head of Unit I in Medical Oncology, Haematology, and Bone Marrow Transplantation at Sarvodaya Hospital in Faridabad. With more than 16 years of clinical experience, he brings deep expertise in diagnosing and treating a broad spectrum of solid and haematological malignancies. His comprehensive training at the Regional Cancer Centre, Trivandrum, combined with his qualifications in internal medicine and general medicine from Government Medical College, Calicut, has established a strong academic and clinical foundation. Dr. Hari's clinical proficiency encompasses the management of leukaemia, lymphoma, myeloma, breast cancer, sarcoma, gastrointestinal cancers, and genitourinary cancers. He is highly skilled in advanced treatment modalities including stem cell transplantation, cancer immunotherapy, targeted therapy, CAR-T cell therapy, and precision oncology. His expertise in oncology critical care ensures that patients with complex presentations receive comprehensive, multidisciplinary support throughout their treatment journey. International patients from the Gulf region, Africa, and South Asia seek Dr. Hari's care for complex oncology cases. He maintains a patient-centric approach, taking time to explain treatment options in clear language and ensuring families understand the clinical pathway. His experience treating international patients has equipped him with cultural sensitivity and a commitment to coordinating care seamlessly across borders. Sarvodaya Hospital, located in Sector 8 of Faridabad, is an established tertiary cancer centre with state-of-the-art oncology facilities, dedicated haematology-BMT units, and comprehensive critical care infrastructure. The hospital prioritizes international patient support with dedicated consultation coordinators, translation services, and streamlined admission processes. Patients from overseas benefit from the hospital's integration of global treatment protocols with local expertise, making complex cancer care both accessible and affordable. International patients considering treatment in India should know that Dr. Hari's unit maintains standards aligned with ASCO and ESMO guidelines, ensuring evidence-based care regardless of origin. Gaf Healthcare can facilitate initial video consultations, arrange document reviews, and coordinate logistics for international patients seeking second opinions or comprehensive oncology management.

Dr. Dipanjan Panda is one of the well-known Medical Oncologists in India, having 15+ years of expertise in treating bone and soft tissue cancers and gastrointestinal cancers. He is credited with starting the country's first anticancer departments and PDCC programme. Dr. Panda developed a medical oncology unit at Indraprastha Apollo Hospital in New Delhi, in association with the Institute of Liver and Biliary Sciences. He is currently working at Indraprastha Apollo Hospital in New Delhi as a Senior Consultant in Medical Oncology. Dr. Panda has written more than twenty peer-reviewed papers in national and international journals and has presented numerous talks at global oncology forums. His clinical interests span targeted therapy, immunotherapy, and the multidisciplinary management of complex gastrointestinal and hepato-pancreato-biliary cancers.

Dr. Bhuvan Chugh is a Lead Consultant in Medical Oncology at Indraprastha Apollo Hospital in New Delhi, bringing over 15 years of clinical excellence to cancer care. He holds qualifications in MBBS, DNB (Medicine), and DNB (Medical Oncology), establishing a robust foundation in internal medicine and specialized oncology practice. Dr. Chugh is recognised for his evidence-based, empathetic approach to patient care, underpinned by a commitment to clarity and confidence in medical decision-making. Dr. Chugh specialises in breast cancer and thoracic cancer management, with particular expertise in chemotherapy, cancer immunotherapy, targeted therapy, and hormone therapy for breast cancers. A key focus of his practice is precision-led oncology—integrating genomic sequencing and molecular oncology findings to guide personalised treatment strategies. His notable clinical work includes CSF-based genomic sequencing management in EGFR-mutant lung cancer with leptomeningeal disease, presented at ALKlinic 2025 and published in the Journal of Liquid Biopsy. He previously served as Principal Consultant at Max Super Specialty Hospital (Saket and Gurugram), and as Past Convenor of the Max Healthcare–Foundation Medicine India Molecular Tumor Board, contributing to multidisciplinary oncology decision-making. Dr. Chugh treats a diverse international patient population, including patients from the Gulf region, Africa, and South Asia seeking specialist cancer care. His fluency in English and Hindi ensures clear communication with patients across borders. He is an active member of leading international oncology societies—American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and International Association for the Study of Lung Cancer (IASLC)—keeping his practice aligned with global standards. His work has been presented at ASCO and ESMO conferences, and he was recognised with the ESMO Asia 2024 Best Poster Award. Indraprastha Apollo Hospital, where Dr. Chugh practices, is a major tertiary-care centre in the Delhi–NCR region with state-of-the-art oncology infrastructure, advanced molecular diagnostics, and dedicated international patient services. The hospital's affiliation with Apollo Athenaa Women's Cancer Centre further strengthens its breast cancer management capabilities. International patients choosing Dr. Chugh benefit from a hospital ecosystem designed to support complex cancer cases, alongside a physician who practises evidence-based protocols informed by global oncology consensus. For patients seeking specialist oncology care with molecular precision and a patient-first philosophy, Dr. Chugh at Apollo Hospitals offers continuity, expertise, and access to cutting-edge diagnostic and therapeutic options.

Dr. Nitesh Rohatgi is the Principal Director of Medical Oncology at Fortis Memorial Research Institute in Gurgaon, India, bringing over 15 years of dedicated clinical expertise in cancer care. He holds prestigious international qualifications including Fellowship of the Royal College of Physicians (Edinburgh) and Fellowship of the Royal Society of Medicine (London), complemented by a postgraduate medical degree from Dundee, UK, and successful completion of oncology training in the UK (CCT, 2009). His clinical training spans medical oncology, palliative medicine, and teenage/young adult cancers in the United Kingdom, establishing a foundation of both Western and Indian oncological best practices. Dr. Rohatgi specializes in the management of solid tumors through a comprehensive range of evidence-based approaches, including chemotherapy (adjuvant, neoadjuvant, and palliative), immunotherapy with immune checkpoint inhibitors, and molecular targeted therapies guided by biomarker analysis. He has served as a Principal Investigator on clinical trials and maintains an active publication record in peer-reviewed journals, positioning him as a key opinion leader in Indian oncology. His approach emphasizes personalized treatment planning, particularly in hormone therapies for breast and prostate cancers, and he routinely manages complex, multidisciplinary cases with clinical precision and scientific rigor. Dr. Rohatgi is experienced in treating international patients from the Gulf region, Africa, and across South Asia, many of whom travel to Gurgaon for his specialized expertise. He brings a compassionate, patient-centered approach to cancer care, understanding the emotional and practical challenges faced by families navigating an oncology diagnosis. His fluency in English and Hindi ensures clear communication with diverse patient populations. Prior to his current role, Dr. Rohatgi worked at the London Oncology Clinic on Harley Street in London, one of the United Kingdom's most respected cancer centers, where he further refined his clinical acumen in a high-volume international setting. Fortis Memorial Research Institute is a NABH-accredited, multi-specialty tertiary care center with state-of-the-art oncology facilities, including dedicated chemotherapy units, advanced diagnostic imaging, and a strong supportive care infrastructure. The hospital attracts international patients through its combination of world-class infrastructure, experienced medical teams, and comprehensive patient support services including translation assistance and international patient liaison offices. Gurgaon's proximity to Delhi and excellent international connectivity make it an ideal destination for medical tourism. For international patients seeking cancer treatment with a physician trained to the highest UK standards but rooted in Indian clinical practice, Dr. Rohatgi offers an evidence-based, compassionate approach backed by years of clinical leadership.

Dr. Mohit Agarwal is the Principal Director and Head of Medical Oncology at Fortis Hospital, Shalimar Bagh, New Delhi, with over 14 years of dedicated experience in comprehensive cancer care. He holds an MBBS from Maulana Azad Medical College, an MD in Medicine from Lady Hardinge Medical College, and a DNB in Medical Oncology from Rajiv Gandhi Cancer Institute. His credentials include the prestigious European Certification in Medical Oncology (ECMO) from the European Society of Medical Oncologists (ESMO), MRCP UK from the Royal College of Physicians, and a Professional Diploma in Clinical Research, demonstrating his commitment to international standards and evidence-based oncology. Dr. Agarwal's clinical expertise spans the full spectrum of modern oncological treatments, including chemotherapy (neoadjuvant, adjuvant, and palliative), immunotherapy, immune checkpoint inhibitor therapy, targeted therapy, molecular-targeted therapy, biomarker-based approaches, and hormone therapy. He specializes in the management of breast cancer, lung cancer, gastro-intestinal malignancies, genitourinary cancers, hepatobiliary carcinoma, and lymphoma. His practice is underpinned by a philosophy that "Cancer Care is Possible," reflected in his meticulous approach to treatment planning and patient outcomes. Dr. Agarwal has established himself as an advocate for accessible and comprehensive cancer care, attracting patients from across India and the Gulf region. He is actively involved in clinical research and teaching, mentoring medical students and residents pursuing medical oncology. His contributions to cancer awareness are evident through his founding of the 'Stop Cancer' initiative, a national and international program that delivers educational lectures, continuing medical education, and patient assistance services. He is a frequent speaker, panelist, and chairperson at major national and international oncology conferences. Fortis Hospital, Shalimar Bagh in New Delhi is equipped with state-of-the-art oncology facilities, advanced diagnostic imaging, and a multidisciplinary cancer care team. The hospital's commitment to safety and quality care makes it a trusted destination for complex cancer treatment. International patients benefit from dedicated support services and seamless coordination for pre-treatment consultations, follow-up care, and management protocols. Patients from Africa, the Gulf Cooperation Council, and Central Asian states often choose Fortis for its combination of expertise, infrastructure, and medical tourism infrastructure, with Gaf Healthcare facilitating smooth access to Dr. Agarwal's services.

Dr. Kunjahari Medhi is a Senior Director of Medical Oncology and Hemato-Oncology at Medanta — The Medicity in Gurugram, one of India's leading tertiary-care institutions. He holds a Doctor of Medicine (DM) in Medical Oncology from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi, and completed his clinical research fellowship at Oxford University as an INDOX Fellow. His educational foundation includes an MBBS from Assam Medical College, where he earned the Gold Medal. Dr. Medhi's clinical expertise spans the full spectrum of cancer care: systemic chemotherapy for solid tumors, both adjuvant and neoadjuvant regimens, immunotherapy using checkpoint inhibitors, and biomarker-driven targeted therapy. He manages patients with solid tumors and hematolymphoid malignancies, offering evidence-based protocols tailored to individual patient biology and disease stage. His practice reflects a commitment to molecular profiling and personalized oncology, ensuring that each patient receives cutting-edge treatment aligned with international standards. Dr. Medhi welcomes international patients from the Gulf region, Africa, and South Asia, leveraging his clinical depth and fluency in both English and Hindi to ensure seamless communication. Medanta — The Medicity provides a comprehensive oncology ecosystem, including dedicated oncology wards, advanced imaging, pathology services, and a robust supportive care team. The hospital maintains NABH accreditation and houses a specialized cancer center with multidisciplinary tumor boards. His additional training in executive management (IIM Ahmedabad) and healthcare leadership (ISB Hyderabad) enables him to navigate complex treatment pathways and coordinate care for international patients. For those seeking evidence-based oncology care in India, Dr. Medhi combines clinical rigor, research exposure, and patient-centered practice.

Dr. Anshul Gupta is a Senior Consultant in Medical Oncology at Indraprastha Apollo Hospital, Delhi NCR, with over 12 years of dedicated cancer care experience. He holds a DM in Medical Oncology from AIIMS, New Delhi, the country's leading cancer medicine institute, combined with an MD in General Medicine and MBBS. Throughout his career, he has treated more than 8,000 cancer patients and administered over 40,000 cycles of chemotherapy, targeted therapy, and immunotherapy, establishing himself as a trusted oncology specialist. Dr. Gupta specializes in a comprehensive range of modern systemic therapies, including chemotherapy, cancer immunotherapy, targeted therapy, hormone therapy, CAR-T cell therapy, and precision oncology. His particular expertise spans breast cancer, genitourinary cancers (prostate and kidney cancer), lung cancer, and soft tissue sarcomas. He integrates international evidence-based guidelines from ASCO and ESMO with practical, patient-centered care tailored to the Indian healthcare context. His international preceptorship in lung cancer at Peter MacCallum Cancer Centre in Melbourne, Australia (2023) further deepens his knowledge of cutting-edge treatment protocols. Dr. Gupta is experienced in treating international patients from the Gulf region, Africa, and South Asia. He communicates fluently in English and Hindi, and Gaf Healthcare's multilingual support team ensures seamless coordination for overseas patients. His patient-centric approach, combined with rigorous clinical training, has earned him a rating of 4.8/5 from over 80 patient reviews. He is a founding member of the Genito-Urinary Cancer Advocacy Network India (GU-CAN India), reflecting his commitment to advancing cancer care beyond the clinic. Indraprastha Apollo Hospital in Delhi NCR is one of India's leading multispecialty healthcare facilities, equipped with state-of-the-art oncology units, advanced diagnostic imaging, molecular pathology laboratories, and dedicated international patient services. The hospital holds international accreditations and offers seamless coordination for medical tourists seeking world-class cancer treatment in India.

Dr. Jasmine Porwal is a Consultant in Medical Oncology and Cancer Care at Medanta — The Medicity in Gurgaon, bringing over 12 years of clinical expertise to comprehensive cancer management. She holds a DM in Medical Oncology from the All India Institute of Medical Sciences (AIIMS) in New Delhi, along with an MD in Internal Medicine from PGIMER – Dr. RML Hospital, New Delhi. Her rigorous training in evidence-based oncology and prior experience as a Senior Research Fellow at AIIMS Delhi (Indian Institute of Rotary Cancer Hospital) have shaped her approach to precision cancer care. Dr. Porwal specializes in the management of solid tumours and haematological malignancies, with particular expertise in chemotherapy regimens—both adjuvant and neoadjuvant—as well as modern immunotherapy and molecular targeted therapy. She is skilled in immune checkpoint inhibitor therapy, manages oncological emergencies with clinical acuity, and provides compassionate palliative care tailored to each patient's goals. Her experience also extends to bone marrow transplantation and complex treatment sequencing under both optimal and resource-constrained settings. She has published her clinical research in leading international journals including the Journal of Clinical Oncology, Annals of Oncology, and Blood, reflecting her commitment to advancing cancer treatment outcomes through rigorous clinical investigation. International patients from the Gulf region, Africa, and SAARC countries form a significant part of her practice. Dr. Porwal is fluent in English and Hindi, ensuring clear communication with patients from diverse backgrounds. She takes a patient-centred approach, discussing treatment options transparently and involving families in decision-making. Her clinic at Medanta welcomes patients seeking second opinions, comprehensive staging, treatment planning, and ongoing supportive care for both newly diagnosed and recurrent cancers. Medanta — The Medicity is a NABH and JCI-accredited tertiary care institution in Gurgaon, known for its comprehensive oncology centre with advanced diagnostic imaging, chemotherapy suites, and integrated palliative services. The hospital's international patient desk, dedicated translators, and streamlined admission processes make it a preferred destination for cancer patients across South Asia, the Middle East, and Africa seeking world-standard care at reasonable costs. Dr. Porwal's tenure at premier institutions including Safdarjung Hospital and the National Cancer Institute, Jhajjar, has further refined her expertise in managing complex oncological scenarios and leading clinical trials. Patients choosing Dr. Porwal benefit from her evidence-based, compassionate approach and access to Medanta's state-of-the-art facilities. International patients are advised to connect via Gaf Healthcare to arrange initial video consultations, document review, and streamlined travel and treatment planning for their cancer care journey.

Dr. Rajit Rattan is a Consultant in Medical Oncology at Medanta – The Medicity, Gurugram, one of India's leading tertiary cancer care centres. With over 12 years of clinical experience and a robust international credential base, Dr. Rattan combines evidence-based medicine with a patient-centric approach to deliver comprehensive cancer management. He holds the MRCP (UK) Clinical Certificate in Medical Oncology and ESMO certification from the European Society of Medical Oncology, ensuring his practice aligns with the highest global standards. Dr. Rattan's clinical expertise spans the full spectrum of solid organ malignancies—lung, breast, gynaecological, gastrointestinal, and urological cancers. His treatment portfolio includes chemotherapy, immunotherapy, targeted therapy, biomarker-based precision medicine, and palliative care. He has been recognised for his academic contributions, including a Bronze Medal in MD Radiotherapy and Oncology from PGIMER Chandigarh (2014), and has presented original research at national and international conferences. His published work appears in peer-reviewed journals such as the Annals of Translational Medicine and the British Journal of Radiology. Dr. Rattan regularly treats international patients from the Gulf region, Africa, and South Asia who seek advanced oncology care without leaving their home countries for routine consultations. He offers telemedicine consultations, detailed case reviews, and coordinated care pathways that make it easy for overseas patients to access world-class treatment planning. His fluency in English and Hindi, combined with his experience managing culturally diverse patient populations, ensures clear communication and comfort throughout the treatment journey. Medanta – The Medicity is a JCI-accredited, 1,200-bed multispecialty institution renowned for its comprehensive oncology services, state-of-the-art imaging, and dedicated chemotherapy infusion centres. The hospital's international patient services team ensures seamless coordination of travel, accommodation, and follow-up care. International patients appreciate the hospital's transparent pricing, English-speaking staff, and access to the latest immunotherapy and targeted therapy protocols. Dr. Rattan's practice at Medanta offers the clinical rigour of a major cancer centre combined with the personalised attention that international patients value when choosing their oncology care abroad.

Dr. Vineet Govinda Gupta is an Additional Director and Unit Head of Medical Oncology at Fortis Hospital, Shalimar Bagh, New Delhi, bringing over 12 years of clinical expertise in comprehensive cancer care. A graduate of the All India Institute of Medical Sciences (AIIMS), New Delhi, he holds an MBBS, MD in Medicine, and a DM in Medical Oncology, achieving Gold Medal distinction in his oncology specialization. He is also a European Certified Medical Oncologist (ECMO), reflecting his commitment to international standards of evidence-based cancer treatment. Dr. Gupta's clinical depth spans chemotherapy for solid tumors, adjuvant and neoadjuvant regimens, palliative chemotherapy, immune checkpoint inhibitor therapy, immunotherapy for advanced malignancies, biomarker-based targeted therapy, and molecular-targeted approaches. He has particular expertise in hormone therapy for breast, prostate, and gynaecologic cancers. His research contributions include publications in top-tier international journals such as the Journal of Clinical Oncology, The Lancet Oncology, and the New England Journal of Medicine. Notably, he led one of India's first retrospective studies on immunotherapy drugs in 2018, establishing himself as a thought leader in cancer immunology. Dr. Gupta is known for treating international patients from the Gulf States, Africa, and across South Asia with the same rigorous, evidence-based approach and personal compassion he brings to all patients. He views each case through the lens of personalized medicine, integrating molecular insights and genomic profiling to tailor treatment plans. His philosophy centres on treating every patient as he would his own family, ensuring comfort, clarity, and the best possible outcomes throughout their cancer journey. Fortis Hospital, Shalimar Bagh, is a leading quaternary-care institution in Delhi equipped with advanced oncology facilities, dedicated ICU support, and a well-established international patient services desk. The hospital's accreditations and state-of-the-art infrastructure make it an ideal destination for international cancer patients seeking world-standard treatment. New Delhi's strategic location, combined with Fortis's reputation for clinical excellence and affordability, positions it as a preferred hub for medical tourists across the Middle East, Africa, and Central Asia seeking specialist oncology care.

Dr. Pooja Babbar is a highly motivated and enthusiastic medical oncologist with over 11 years of experience in the field. She holds a DM in Medical Oncology (Gold Medalist) from the prestigious Kidwai Memorial Institute of Oncology, Rajiv Gandhi University of Health Sciences (RGUHS), where she was awarded a gold medal for her outstanding academic performance. She has extensive expertise in the evaluation, diagnosis, staging, and formulation of personalised care plans for both solid and haematological malignancies. She remains well-versed with the latest advancements in cancer care, adhering to international protocols and evidence-based guidelines to ensure optimal treatment outcomes. Dr. Babbar holds a European Certification in Medical Oncology from ESMO and has been trained at Tata Memorial Hospital, Mumbai. Known for her empathetic nature and patient-centric approach, she is committed to delivering comprehensive and holistic oncology care. Her patients trust her for her expertise, compassion, and commitment to cutting-edge cancer treatment.

Dr. Huma Noor has joined as a Consultant in Medical Oncology at Fortis Escorts, Okhla Road, New Delhi. She has over 11 years of experience in the field of oncology. Dr. Noor is fully proficient in all aspects of medical oncology, including diagnosis and treatment of all types of cancers — solid and liquid cancers. Furthermore, she also treats less common malignancies like soft tissue sarcomas, bone sarcomas, and paediatric malignancies. She has clinical expertise in chemotherapy, immunotherapy, targeted therapy and hormonal therapy, besides supportive and pain & palliative care. Dr. Noor has performed more than fifty stem cell transplants. She has been first in her state to carry out successful paediatric transplant. She is an active member of various international and national oncology societies including ASCO, ESMO, ISMPO, etc.

Dr. Joydeep Singh Vasant is an Associate Consultant in Medical Oncology at Medanta - The Medicity in Gurgaon, bringing over 11 years of clinical experience in comprehensive cancer care. He holds an MD in Radiation Oncology from PGIMS, Rohtak (2019), and has recently completed his DM in Medical Oncology from MG Institute of Medical Sciences and Research, Jaipur (2025). He is certified by the European Society of Medical Oncology (ESMO) in both Medical Oncology and Pain and Palliative Care, reflecting his commitment to evidence-based, patient-centered cancer management. Dr. Vasant demonstrates clinical depth across a broad spectrum of malignancies. He manages solid tumors including lung, breast, head and neck, genitourinary, and gynaecological cancers, alongside sarcomas and complex hematological malignancies such as lymphomas, multiple myeloma, myeloproliferative disorders, and acute leukemias. His treatment portfolio spans chemotherapy (adjuvant and neoadjuvant), immunotherapy for advanced cancers, targeted therapies, hormone therapy for breast cancer, intrathecal chemotherapy, and autologous stem cell transplantation. His work has been recognized professionally, earning a 1st Prize for Best Paper at the AROI North Zone conference in 2020. Dr. Vasant is known for his compassionate approach to international patients. He regularly treats patients from the Gulf states, Africa, and across South Asia seeking oncology expertise in India. His bilingual communication in English and Hindi ensures clear dialogue about complex treatment plans, and Medanta's international patient support team facilitates seamless coordination for overseas patients requiring extended care. Medanta - The Medicity is one of India's leading multi-specialty hospital chains, recognized for its state-of-the-art oncology facilities, experienced multidisciplinary tumor boards, and robust supportive care infrastructure. The hospital's NABH accreditation and comprehensive ICU capabilities ensure international standards of care. For patients from abroad, the hospital's dedicated international desk provides visa support, accommodation coordination, and family counselling services, making Gurgaon an accessible destination for complex cancer management. International patients considering treatment with Dr. Vasant should know that India's medical tourism framework combines world-class expertise with significantly lower treatment costs compared to Western centers. The Gurgaon location offers modern amenities, English-speaking staff, and a thriving expatriate community, making the treatment journey smooth for families traveling from overseas.

Dr. Suhail Qureshi is an Additional Director and Unit Head of Medical Oncology at Fortis Hospital, Shalimar Bagh, New Delhi, bringing 11 years of dedicated clinical experience in the diagnosis and treatment of diverse malignancies. He is a highly trained medical oncologist with advanced qualifications from some of India's most respected institutions, including a fellowship in Medical Oncology, Hematology and Bone Marrow Transplantation from Medanta, The Medicity, Gurugram. Dr. Qureshi's clinical expertise spans the full spectrum of cancer care, from chemotherapy for solid tumors and hematologic malignancies to advanced immunotherapy and molecular targeted therapies. He has specialized training in adjuvant and neoadjuvant chemotherapy, palliative oncology, hormone therapies for breast and prostate cancers, and autologous bone marrow transplantation. His comprehensive approach ensures that each patient receives individualized treatment tailored to their cancer type, stage, and overall health status. With a patient-centered philosophy, Dr. Qureshi is experienced in managing international patients seeking oncology care from the Gulf region, Africa, and the SAARC countries. He combines evidence-based treatment protocols with compassionate support, making him a trusted choice for families navigating complex cancer diagnoses. His active engagement with international oncology conferences and contributions to peer-reviewed publications demonstrate his commitment to staying current with evolving treatment paradigms. Fortis Hospital, Shalimar Bagh is a leading tertiary care center in New Delhi, accredited with advanced oncology infrastructure, multimodal imaging, and supportive care facilities. The hospital's international patient services team facilitates seamless coordination for overseas patients, including visa assistance, accommodation guidance, and multilingual support. For international patients choosing treatment in New Delhi, Dr. Qureshi's expertise combined with Fortis's world-class facilities offers comprehensive, accessible cancer care.

Dr. Imran Khan has joined as a Consultant in Medical Oncology at Fortis Escorts, Okhla Road, New Delhi. He has over 10 years of experience in the field of oncology. Dr. Khan has experience in treating all types of cancers — solid and liquid cancers. Additionally, he is experienced in treating rare malignancies like soft tissue sarcomas and bone sarcomas, as well as paediatric malignancies. He has rich experience in all aspects of medical oncology, including administering chemotherapy, targeted drugs, immunotherapy drugs, antibody-drug conjugate drugs, as well as pain and palliative care. Dr. Khan has experience in performing various procedures such as PICC line insertion, bone marrow aspiration and biopsy, intrathecal administration of drugs, and ascitic fluid drainage. He is an active member of ASCO, ESMO, CAMO, UKAOS, MOGA, AIOM, SFPPO, CSCO, and ISMPO. Dr. Khan has been an active participant as a speaker and panelist in various international and national conferences. He has multiple medical publications in various international and national journals and is reviewer for numerous oncological manuscripts.

Dr. Ankur Mudgal is a Consultant in Medical Oncology at Medanta – The Medicity, Gurugram, one of India's leading multi-specialty healthcare institutions. With over 10 years of clinical experience in oncology, Dr. Mudgal has established himself as a compassionate and evidence-based practitioner dedicated to delivering personalized cancer care. He holds qualifications in MBBS, MD, and DNB, and has completed advanced training in immuno-oncology through a preceptorship conducted by the European Society of Medical Oncology in Singapore—a credential that reflects his commitment to staying at the forefront of modern cancer therapeutics. Dr. Mudgal's clinical expertise spans the full spectrum of systemic cancer treatment, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. He brings particular depth in managing breast, lung, gastrointestinal, and genitourinary malignancies. His special interest in immune checkpoint inhibitor therapy and precision oncology allows him to tailor treatment strategies to each patient's tumor biology and clinical context. Beyond curative approaches, Dr. Mudgal is equally invested in palliative care and geriatric oncology, ensuring that elderly patients and those with advanced disease receive compassionate, symptom-focused support alongside disease-modifying therapies. Dr. Mudgal regularly treats patients from across the Gulf region, Africa, and South Asia who seek specialized oncology care in India. His fluency in both English and Hindi, combined with his patient-centered philosophy, makes him accessible and reassuring to international patients navigating complex cancer diagnoses. He takes time to explain treatment options, potential outcomes, and quality-of-life considerations in clear, understandable terms, empowering families to make informed decisions about their care. Medanta – The Medicity in Gurugram is a 650-bed tertiary care facility with advanced oncology infrastructure, including state-of-the-art chemotherapy units, medical imaging, and dedicated palliative care teams. The hospital's multi-disciplinary tumor boards, robust infection control protocols, and international patient services make it an ideal destination for comprehensive cancer care. Patients benefit from seamless coordination with surgical oncology, radiation oncology, and supportive care specialists, ensuring holistic treatment journeys. For international patients considering cancer treatment in India, Dr. Mudgal offers evidence-based, compassionate care grounded in the latest advances in medical oncology. Whether seeking a second opinion, curative-intent treatment, or palliative support, patients can expect a thoughtful, personalized approach designed to optimize both disease control and quality of life.

Dr. Kumar Rishikesh is a Senior Consultant in Medical Oncology at Indraprastha Apollo Hospital, New Delhi, with over 10 years of dedicated clinical experience in cancer care. He holds an impressive educational background that includes MBBS, MD (Medicine), DNB in Medical Oncology, and a prestigious Fellowship in Medical Oncology and Hematology from Princess Margaret Cancer Centre at the University of Toronto, Canada. This international training has equipped him with expertise in cutting-edge oncological practices and a global perspective on cancer treatment. Dr. Rishikesh brings substantial clinical depth across a comprehensive range of malignancies, from solid tumors like breast, gastric, and gynecologic cancers to hematologic conditions including leukemia, lymphoma, and myeloma. His areas of specialization encompass conventional chemotherapy, advanced immunotherapy, targeted molecular therapy, hormone-based treatments, and emerging modalities such as CAR-T cell therapy. He actively participates in multidisciplinary molecular tumor boards and has contributed to research on neoadjuvant chemotherapy response and treatment optimization, reflecting his commitment to evidence-based, personalized cancer care. Dr. Rishikesh is well-accustomed to treating international patients from the Gulf region, Africa, and South Asia seeking specialized oncology care. His fluency in English, Hindi, Bengali, and Maithili enables seamless communication with patients from diverse linguistic backgrounds, ensuring clear discussion of treatment plans, prognosis, and support options. He approaches each patient with compassion and takes time to understand their individual circumstances, cultural needs, and treatment preferences. Indraprastha Apollo Hospital is one of India's leading multispecialty institutions, equipped with state-of-the-art oncology facilities, advanced imaging and laboratory capabilities, and a strong multidisciplinary team. The hospital's commitment to international patient care, NABH accreditation, and robust follow-up infrastructure make it a trusted destination for comprehensive cancer treatment. Dr. Rishikesh's practice there combines world-standard diagnostic protocols, modern chemotherapy regimens, and compassionate supportive care, making it an excellent choice for international patients seeking reliable, evidence-based oncology treatment in South Asia.

Dr. Suman Karanth Gupta is an Additional Director of Medical Oncology at Fortis Memorial Research Institute in Gurugram, with over 10 years of dedicated clinical experience in oncology. She holds an MBBS, MD in Internal Medicine, and a DNB in Medical Oncology, complemented by a Clinical Research Fellowship in Gynaecological Malignancies from The Christie Hospital, Manchester, UK—Europe's largest single-site comprehensive cancer centre. Her international training and rigorous academic credentials position her as a leader in precision oncology. Dr. Gupta specialises in chemotherapy for solid tumours, molecular targeted therapy, biomarker-based treatment strategies, and immunotherapy for advanced cancers. She has particular expertise in gynaecological malignancies, neuro-oncology, and colorectal cancers. During her fellowship at Christie Hospital, she actively participated as a sub-investigator in Phase 1–3 clinical trials and undertook a clinical observership in the Intestinal Failure Unit at Salford Royal Hospital, UK, where she gained specialised knowledge in managing malignant bowel obstruction and parenteral nutrition support. Her approach integrates cutting-edge molecular profiling with compassionate patient-centred care. Dr. Gupta treats a diverse international patient population, including patients from the Gulf states, Africa, and the Indian subcontinent. She is fluent in English and Hindi, and ensures seamless communication with overseas patients through video consultations and detailed case reviews. Her commitment to quality of life during cancer treatment has earned her a strong reputation among international patients seeking evidence-based, personalised oncology care. Fortis Memorial Research Institute, where Dr. Gupta practises, is one of India's premier tertiary-care teaching hospitals, equipped with state-of-the-art diagnostic and therapeutic facilities. The institute is NABH and JCI-accredited, offers advanced imaging, molecular pathology laboratories, and dedicated oncology suites. Its robust international patient services department, multilingual support, and streamlined visa assistance make it an ideal destination for global patients seeking seamless, high-quality cancer treatment. International patients choosing Dr. Gupta benefit from her fusion of European training standards with Indian healthcare excellence, coupled with affordable treatment costs and minimal waiting times. Her holistic approach—combining precision medicine with emotional wellness—ensures that every patient receives world-class care in a supportive environment.

Dr. Ghazal Tansir is a Senior Consultant in Medical Oncology at Indraprastha Apollo Hospital in New Delhi, bringing over 9 years of focused expertise in cancer diagnosis and treatment. She holds advanced qualifications including a DM in Medical Oncology, MD in Internal Medicine, DNB, and MBBS, establishing a robust academic and clinical foundation. Her training and sustained practice reflect a deep commitment to staying at the forefront of oncological science. Dr. Tansir specializes in a comprehensive range of cancer types including breast cancer, lung cancer, head and neck cancers, genitourinary malignancies, and sarcoma. She is highly proficient in evidence-based treatment modalities including chemotherapy, cancer immunotherapy, targeted molecular therapy, hormone therapy, and emerging CAR-T cell therapy protocols. Her clinical approach emphasizes personalized treatment planning, integrating the latest research findings with individual patient circumstances to optimize both efficacy and quality of life. She regularly treats international patients from the Gulf region, Africa, and South Asia, providing clear multilingual communication and coordinated care pathways. Her patient-centric philosophy ensures families are supported throughout the cancer journey with transparent information and compassionate clinical guidance. Indraprastha Apollo Hospital is a premier multi-specialty tertiary care centre known for its advanced oncology infrastructure, dedicated cancer wards, state-of-the-art radiation and chemotherapy units, and integrated supportive care. The hospital's international patient services and established ties with global oncology networks make it an ideal destination for complex cancer management. International patients choosing Dr. Tansir benefit from seamless coordination through Gaf Healthcare, ensuring smooth travel logistics, pre-arrival case review, and comprehensive follow-up care planning.

Dr. Ashutosh Jain is an Associate Consultant in the Department of Medical Oncology at Fortis Memorial Research Institute in Gurgaon, bringing over 8 years of clinical expertise in comprehensive cancer care. He holds a DM in Medical Oncology alongside his MD and MBBS qualifications, positioning him as a fully trained medical oncologist with deep subspecialty knowledge. Dr. Jain has developed extensive clinical experience across a broad spectrum of malignancies, including breast cancer, lung cancer, gastrointestinal cancers, head and neck cancers, brain tumors, urological cancers, gynecological cancers, lymphomas, leukemias, and myelomas. His areas of clinical focus encompass chemotherapy for solid tumors, immunotherapy approaches, targeted molecular therapy, hormone therapy for breast cancer, and advanced stem cell transplantation. He is particularly skilled in adjuvant and neoadjuvant chemotherapy protocols, palliative care optimization, and both autologous and allogeneic bone marrow transplantation for hematologic malignancies. Throughout his career, Dr. Jain has been affiliated with several prestigious cancer centers, including the Tata Memorial Research Institute in Mumbai—one of India's leading oncology institutions—and Banaras Hindu University in Uttar Pradesh. His training at these elite centers has instilled a commitment to evidence-based practice and continuous advancement in cancer treatment paradigms. He actively engages in academic activities and research, ensuring his clinical practice reflects the latest advances in oncology. At Fortis Memorial Research Institute in Gurgaon, Dr. Jain provides patient-centered oncologic care to both local and international patients. The hospital is well-equipped with modern diagnostic and treatment facilities, making it a trusted destination for patients seeking specialized cancer care. International patients from the Gulf region, Africa, and across South Asia regularly travel to Gurgaon for consultation and treatment under his care, benefiting from the hospital's international patient support services and his fluency in English and Hindi. Dr. Jain's approach combines rigorous clinical judgment with compassionate patient communication. He takes time to explain complex treatment options, potential outcomes, and quality-of-life considerations, ensuring that patients make informed decisions aligned with their individual circumstances and values. For international patients, Gaf Healthcare facilitates seamless access to his expertise through remote consultations, comprehensive medical record review, and coordinated care planning.

Dr. Bhawna Dahiya is a Consultant in Medical Oncology at Sarvodaya Hospital in Faridabad, with over 8 years of dedicated clinical experience in cancer care. She holds a DM in Medical Oncology from Government Kilpauk Medical College, Chennai, and is certified by the European Society of Medical Oncology (ESMO), reflecting her commitment to evidence-based, contemporary oncology practice. Dr. Dahiya brings deep expertise across the full spectrum of medical oncology, with specialization in breast cancer, gynaecologic malignancies, thoracic cancers, gastrointestinal malignancies, and lymphoproliferative disorders. She is proficient in chemotherapy administration, targeted therapy, cancer immunotherapy, and CAR-T cell therapy. Her clinical approach emphasizes personalized treatment planning, oncologic emergency management, and supportive palliative care to optimize patient outcomes. She welcomes international patients from the Gulf region, Africa, and South Asia, and is experienced in coordinating multidisciplinary care for overseas families. Her calm, patient-centred approach helps international patients navigate complex treatment decisions with confidence. She is fluent in English and Hindi, facilitating clear communication with diverse patient populations. Sarvodaya Hospital, where Dr. Dahiya practices, is a modern, NABH-accredited facility in Sector 8, Faridabad, offering advanced oncology infrastructure, dedicated cancer wards, ICU support, and a dedicated international patient coordination team. The hospital's proximity to Delhi makes it accessible for patients from across India and the world. International patients benefit from streamlined admission processes, telemedicine pre-consultation, and comprehensive discharge planning for continued care at home.

Dr. Devanshee Aakash Shah is an accomplished Medical Oncologist with over 8 years of clinical experience in managing complex cancer cases. She holds an MBBS from BJMC, MD in Internal Medicine, and a DM in Medical Oncology from NHL MMC, complemented by advanced certifications including Harvard Medical School eDiploma in Advanced Management of Oncological Diseases and ESMO certification from the European Society of Medical Oncology. Currently serving as Associate Consultant in Medical Oncology at Paras Hospitals in Gurugram, Dr. Shah brings a comprehensive, evidence-based approach to cancer diagnosis and treatment. Dr. Shah's clinical expertise spans a broad spectrum of oncological conditions, including lung cancer, head and neck cancers, hematological malignancies, breast and gynecological cancers, gastrointestinal cancers, and genitourinary cancers. She specializes in chemotherapy for solid tumors, adjuvant and neoadjuvant chemotherapy, immunotherapy for advanced cancer, immune checkpoint inhibitor therapy, molecular targeted therapy, and biomarker-based treatment protocols. Her proficiency in autologous bone marrow transplantation and multiple myeloma management reflects her depth in complex hematologic malignancies. With ECMO certification and extensive clinical volumes, she combines technical precision with personalized cancer care strategies. Dr. Shah is highly experienced in treating international patients seeking specialized oncology care in India. She welcomes patients from the Gulf region, Africa, and Southeast Asia, offering multilingual support in English and Hindi. Her patient-centered approach emphasizes quality of life, novel treatment protocols, and collaborative care planning. She previously served as Assistant Professor at Tata Memorial Hospital, Mumbai—one of India's foremost cancer research and treatment centers—an experience that strengthened her commitment to clinical excellence and evidence-based practice. Paras Hospitals in Gurugram is a nationally accredited, multispecialty tertiary care center known for its oncology department, advanced diagnostic imaging, and comprehensive cancer support services. The hospital attracts international patients due to its NABH accreditation, experienced oncology team, and cost-effective treatment protocols compared to Western centers. Dr. Shah's affiliation with Paras places her at a hub of cancer care innovation, where she integrates cutting-edge therapies with compassionate patient management. International patients choosing Dr. Shah benefit from world-class oncology expertise at a fraction of the cost available in Europe or North America, combined with personalized follow-up care and seamless coordination through Gaf Healthcare.

Dr. Mukesh Patekar is an Associate Director of Medical Oncology at BLK-Max Super Speciality Hospital in New Delhi, bringing over 8 years of dedicated clinical experience in comprehensive cancer care. He holds an MD in General Medicine and a DM in Medical Oncology, complemented by his foundational MBBS qualification. His training at the All India Institute of Medical Sciences (AIIMS), one of India's premier medical institutions, has equipped him with advanced expertise in evidence-based oncological management. Dr. Patekar's clinical practice spans a broad range of solid malignancies, including sarcoma, bone cancer, head and neck cancer, thoracic and lung cancer, breast cancer, thyroid cancer, urological cancer, gastrointestinal cancer, and gynaecological cancer. He specialises in chemotherapy protocols—both adjuvant and neoadjuvant—palliative care, and the emerging fields of immunotherapy, immune checkpoint inhibitor therapy, and molecular targeted therapy. His approach integrates biomarker-based strategies and molecular profiling to personalise cancer treatment, ensuring each patient receives care tailored to their tumour's biological characteristics. Throughout his career, Dr. Patekar has served at leading hospitals across the Delhi-NCR region, including Artemis Hospitals in Gurugram, where he held the position of Unit Head and Senior Consultant, and Fortis Memorial Research Institute (FMRI). His reputation for a patient-centric approach has made him a sought-after oncologist for both domestic and international patients. He routinely treats patients from the Gulf region, Africa, and South Asia who seek world-class cancer care in India. BLK-Max Super Speciality Hospital is a state-of-the-art NABH-accredited facility in New Delhi with comprehensive oncology infrastructure, dedicated chemotherapy suites, advanced diagnostic imaging, and dedicated support for international patients. The hospital's multidisciplinary tumour boards and access to the latest treatment protocols make it an ideal destination for complex cancer cases. International patients choosing Dr. Patekar benefit from streamlined admission processes, English-language medical documentation, and coordinated follow-up care through Gaf Healthcare's global patient network.

Dr. Mehak Trehan is an Associate Consultant in Hemato-Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurgaon. A Clinical Hematologist and Hemato-Oncologist with over 6 years of professional experience, she brings a distinguished academic background marked by exceptional achievements across all stages of her medical training. Dr. Trehan completed her MBBS (Hons.) as Best Outgoing Student and earned a Gold Medal in her MD in Medicine for academic excellence. She further specialised with a DM in Clinical Hematology from the All India Institute of Medical Sciences (AIIMS), New Delhi — one of India's premier medical institutions — where she was again awarded a Gold Medal for outstanding performance. Dr. Trehan's clinical expertise spans the full spectrum of hematological malignancies and blood disorders. She specialises in treating acute and chronic leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes. Her particular clinical focus includes bone marrow transplantation, including haploidentical transplant procedures, chemotherapy for blood cancers, and cancer immunotherapy. She has developed strong technical and clinical competencies in managing complex blood disorders such as thalassemia and sickle cell disease, combining evidence-based medicine with compassionate patient care. Dr. Trehan is committed to serving international patients seeking expert hematologic care. She welcomes patients from the Gulf region, Africa, and the broader SAARC region, providing professional consultation and treatment planning in English and Hindi. Her practice at Fortis Memorial Research Institute positions her to manage both routine and highly complex cases, offering continuity of care and access to advanced diagnostic and therapeutic technologies. She maintains active membership in several prestigious national and international societies, including ASCO, SOHO, ASTCT, ISHBT, and the MHG Group, ensuring her practice remains aligned with global standards in hematology and oncology. Fortis Memorial Research Institute in Gurgaon is a leading multi-specialty tertiary care facility renowned for its haematology and oncology departments. The hospital is equipped with state-of-the-art diagnostic facilities, ICU support, and specialised wards for cancer and transplant patients. Its international patient services desk, NABH accreditation, and track record in managing complex blood cancers make it a preferred destination for patients seeking advanced hematologic care. International patients benefit from coordinated care pathways, dedicated translators, and organised logistics support, ensuring a seamless treatment experience in India.

Dr. Nitesh Anand is an Associate Consultant in Medical Oncology at Medanta — The Medicity, Gurugram, bringing over 5 years of clinical expertise in the diagnosis and management of both solid and haematological malignancies. His strong academic foundation includes a DM in Medical Oncology from Rajiv Gandhi University of Health Sciences, Bangalore, complemented by DNB training from the Chittaranjan National Cancer Institute in Kolkata, one of India's premier oncology centres. This rigorous training pathway has equipped him with deep knowledge in evidence-based cancer care. Dr. Anand specialises in a comprehensive range of modern oncological therapies, including chemotherapy for solid tumours, neoadjuvant and adjuvant regimens, immunotherapy using immune checkpoint inhibitors, and molecular-targeted therapies guided by biomarker analysis. His SITC Certification in Cancer Immunotherapy underscores his expertise in immuno-oncology, a rapidly evolving field where he remains actively engaged. He treats diverse cancer types, from cervical cancer and myeloma to lymphoma and sarcoma, using personalised treatment strategies tailored to each patient's tumour biology and clinical status. Dr. Anand is experienced in welcoming international patients from across the Gulf, Africa, and South Asia who seek advanced cancer care in India. He communicates fluently in English and Hindi, ensuring clear dialogue with patients from diverse backgrounds. His approach emphasises translational oncology research, meaning he brings insights from the latest clinical trials and scientific literature into his day-to-day practice, often discussing novel biomarkers and emerging therapies with his patients. Medanta — The Medicity in Gurugram is renowned for its integrated cancer centre with state-of-the-art chemotherapy units, dedicated oncology wards, and access to molecular diagnostic laboratories for real-time biomarker testing. The hospital's NABH and JCI accreditations, combined with its 24/7 critical care infrastructure, make it a trusted destination for complex oncological cases. International patients benefit from the hospital's dedicated concierge services, multilingual support teams, and streamlined visa and logistical coordination through partners like Gaf Healthcare. For international patients considering treatment in India, Dr. Anand represents the calibre of oncologist you can expect at tertiary centres like Medanta: formally trained, research-minded, and fully equipped to manage advanced malignancies with cutting-edge therapies. Whether you need a second opinion on your cancer diagnosis or comprehensive management, a video consultation with Dr. Anand through Gaf Healthcare can clarify your options and treatment timeline.

Dr. Bhaarat is a Consultant Hemato-Oncologist at Medanta — The Medicity in Gurugram, specializing in the diagnosis and treatment of blood cancers and hematological disorders. He holds an MBBS degree, an MD in Medicine, and a DrNB in Clinical Hematology from the prestigious Rajiv Gandhi Cancer Institute & Research Centre, New Delhi (2018–2021), where he trained under nationally recognized hemato-oncologists. His expertise spans the full spectrum of hematological malignancies and benign blood disorders. With over 5 years of clinical experience, Dr. Bhaarat has personally participated in more than 100 bone marrow transplant procedures, including autologous, matched sibling donor (MSD) allogeneic, matched unrelated donor (MUD) allogeneic, and haploidentical haematopoietic stem cell transplants (HSCT). He is proficient in managing acute and chronic leukemia, lymphoma, multiple myeloma, and bone marrow failure syndromes. His procedural skills include bone marrow aspiration and biopsy, lumbar puncture, intrathecal chemotherapy, and comprehensive hematological diagnostics. He completed the Dana-Farber Cancer Institute's Acute Lymphoblastic Leukemia Preceptorship Program, further refining his approach to complex leukemia management. Dr. Bhaarat is known for his patient-centric approach and has built a strong reputation for treating international patients seeking world-standard care in India. He regularly welcomes patients from the Gulf Cooperation Council (GCC) nations, Africa, and South Asian countries, offering comprehensive consultation, treatment planning, and long-term follow-up. His bilingual fluency in English and Hindi ensures clear communication with diverse patient populations, making the medical journey seamless for those traveling to India for specialized hematology and transplant care. Medanta — The Medicity stands as one of India's premier multi-specialty healthcare institutions, featuring state-of-the-art ICU and transplant facilities, NABH accreditation, and an established international patient services team. Located in Gurugram, a major business and healthcare hub near Delhi, the hospital offers convenient access for international travelers and comprehensive support throughout the treatment journey. Patients choosing Dr. Bhaarat benefit from both his specialized expertise and Medanta's world-class infrastructure, making it an ideal destination for those seeking advanced hematology and bone marrow transplant services in South Asia.